Tuesday, July 31, 2012

From Toho U-Japan: Presence of circulating lung cancer tumor cells correlates with EGFR mutation in circulating free DNA

http://www.ncbi.nlm.nih.gov/pubmed/22843912


 2012 Aug;32(8):3339-44.

Clinical Significance of Circulating Tumor Cells and Free DNA in Non-small Cell Lung Cancer.

Source

Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan. kazutoshiisobe@aol.com.

Abstract

Aim: This pilot study assessed correlations between circulating tumor cells (CTCs) and circulating free DNA (cfDNA) of metastatic non-small cell lung cancer (NSCLC) after acquisition of resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

PATIENTS AND METHODS:

CTCs were counted using the CellSearch system (Veridex). cfDNA was analyzed for EGFR mutation status by the Cycleave real-time PCR assay.

RESULTS:

Twenty-four patients participated in this study. CTCs were detected in 8 of 24 cases (33.3%), at a mean of 2.6 CTCs per 7.5 ml blood (range: 1-24). EGFR mutations in cfDNA were detected in 6 out of 24 cases (25%). The EGFR mutation detection rates in cfDNA were significantly higher in patients with ≥2 CTCs per 7.5 ml (100%) than in those with <2 CTCs per 7.5 ml (10%) (p=0.0001).

CONCLUSION:

The presence of CTCs was correlated with the positivity of EGFR mutation in cfDNA.

No comments:

Post a Comment